Abstract 2045P
Background
The success of cancer therapy relies on patient adherence, which refers to the extent to which a person's behaviour - taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider ( WHO 2003 ). Several PROMs were developed to measure patient adherence to (cancer) therapy. In light of this, our study aims to offer a comprehensive overview of PROMs in the cancer field, with a specific focus on the adherence dimensions captured.
Methods
A systematic review of systematic reviews was performed to identify studies of cancer patients that apply PROMs to measure adherence without restriction to the type of therapy. Databases of Pubmed and Embase were searched up to March 2022 and studies were selected based on predefined eligibility criteria. A qualitative synthesis was used determining measurement of adherence and dimensions of PROMs according to the WHO definition for adherence.
Results
After screening 4483 results a total of 56 literature reviews were included capturing 1064 studies that focused on cancer patients. Out of the 56 literature reviews included in our final analysis, the majority (45) focused on medication adherence, while 18 studies assessed adherence to dietary recommendations, and 13 studies examined adherence to lifestyle changes. Three studies investigated other dimensions of adherence. Data collection was primarily carried out via questionnaires and most studies applied self-developed, non-validated PROMs. PROMs mainly measured one dimension of adherence, even though the content of items were overlapping between medication, diet and lifestyle.
Conclusions
This systematic literature review provides a comprehensive overview of PROMs used to assess adherence in oncology. Our analysis highlights the predominance of studies measuring medication adherence and underscores the need for greater attention to other dimensions of adherence. Our findings can inform the choice of PROMs to monitor patients’ adherence in clinical practice and enhance health outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06